Evidence map›Paper›PMID 41943118›Full record

ArticleVirology journal2026

The viral and host genomic landscape of human T-cell leukemia virus type I in Peru.

Daniel Enriquez-Vera, Jiazhou Li, Jorge Nakazaki-Aza, Kosuke Mochida, Yutaka Suzuki, Eduardo Gotuzzo, Martín Montes, Kazuhiro Morishita, Shingo Nakahata

Abstract read
In one paragraph

Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel Enriquez-VeraDivision of HTLV-1/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima-shi, Kagoshima, 890-8544, Japan.
Jiazhou LiDivision of HTLV-1/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima-shi, Kagoshima, 890-8544, Japan.
Jorge Nakazaki-AzaFacultad de Medicina, Instituto de Medicina Tropical 'Alexander von Humboldt', Universidad Peruana Cayetano Heredia, Honorio Delgado 430, San Martin de Porres, Lima, 15102, Peru.
Kosuke MochidaDepartment of Dermatology, Department of Medical Sciences, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Yutaka SuzukiLaboratory of Systems Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Chiba, 277-8561, Japan.
Eduardo GotuzzoFacultad de Medicina, Instituto de Medicina Tropical 'Alexander von Humboldt', Universidad Peruana Cayetano Heredia, Honorio Delgado 430, San Martin de Porres, Lima, 15102, Peru.
Martín MontesFacultad de Medicina, Instituto de Medicina Tropical 'Alexander von Humboldt', Universidad Peruana Cayetano Heredia, Honorio Delgado 430, San Martin de Porres, Lima, 15102, Peru. martin.montes@upch.pe.
Kazuhiro MorishitaDivision of Pediatrics, Department of Developmental and Urological-Reproductive Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. kmorishi@med.miyazaki-u.ac.jp.
Shingo NakahataDivision of HTLV-1/ATL Carcinogenesis and Therapeutics, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima-shi, Kagoshima, 890-8544, Japan. snakahata@kufm.kagoshima-u.ac.jp.

Funding

Japan Society for the Promotion of Science 17H04600Kobayashi Foundation for Cancer Research 2021SK020
6 · The paper itself

Abstract

backgroundThe human T-cell leukemia virus type 1 (HTLV-1) is a neglected oncogenic retrovirus responsible for adult T-cell leukemia/lymphoma (ATLL) and autoimmune diseases that disproportionately affects marginalized populations worldwide. Peru reports the highest global ATLL incidence, yet comprehensive genomic studies remain limited. We aimed to characterize the virological, immunological, and host genetic landscape of HTLV-1 infection to identify population-specific high-risk features.

methodsWe conducted a prospective cohort study (2017-2018) of 67 HTLV-1-infected individuals from Lima, Peru, using an integrated high-throughput genomic approach. This included whole-genome HTLV-1 sequencing, targeted ultra-deep sequencing of 280 hematological malignancy-associated genes, high-resolution HLA typing, GATK-based variant calling, and comprehensive clinical follow-up over 7 years. Phylogenomic analyses were performed using maximum likelihood and Bayesian approaches.

resultsThe cohort exhibited exceptionally high-risk characteristics with a median proviral load (PVL) of 4.5 ± 3.8, and 13.4% cumulative crude mortality over 7 years. Phylogenomic analysis revealed 96.8% of isolates belonged to the Transcontinental subtype, with most clustering in a newly identified Andean-Amazonian subgroup. HLA-I analysis demonstrated unique population-specific allele distributions with significantly reduced evolutionary divergence compared to Japanese cohorts (HLA-HED: 5.34 vs. 6.87, p = 0.0002), potentially differences in mechanisms of viral immune control. Ultra-deep sequencing identified early clonal hematopoiesis with prevalent mutations in cancer-associated genes including KMT2D (55%), NOTCH1 (49%), and TP53 (27%). Mutation burden correlated significantly with proviral load (r = 0.34, p = 0.003), and longitudinal analysis revealed progressive genomic instability with more than two-fold increase in mutations over 3 years (7.25 vs. 19.5 mutations per patient, p = 0.01). High PVL (> 4%) was the only independent predictor of crude mortality (OR: 1.07; 95% CI: 1.01-1.15; p = 0.033). Contrary to previous reports, Strongyloides coinfection was not associated with disease progression.

conclusionsThis first comprehensive genomic characterization of HTLV-1 in South America reveals population-specific viral evolution, reduced HLA diversity, and evidence of early oncogenic transformation events. The exceptionally high proviral loads and unique mutational landscape provide novel insights into HTLV-1 pathogenesis and support the development of population-tailored risk stratification approaches. These findings emphasize the urgent need for expanded genomic surveillance and targeted interventions in underrepresented populations bearing disproportionate HTLV-1 burden.

Indexed as

HTLV-I InfectionsHuman T-lymphotropic virus 1AdultFemaleGenome, ViralGenomicsHigh-Throughput Nucleotide SequencingHumansLeukemia-Lymphoma, Adult T-CellMaleMiddle AgedPeruPhylogenyProspective StudiesProvirusesViral LoadAdult T-CellClonal HematopoiesisHealth DisparitiesHuman T-lymphotropic virus 1Latin AmericaLeukemia-LymphomaNeglected Diseases

Identifiers

PMID41943118
PMCPMC13191997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.